25,729 articles
Istradefylline
Istradefylline (NOURIAST, Nourianz; KW-6002) is a first-in-class adenosine A2A receptor antagonist taken once daily with levodopa for OFF episodes in Parkinson's disease; approved in Japan 2013 and by the FDA in 2019.
Isunakinra
Isunakinra (formerly EBI-005) is a recombinant fusion protein that blocks interleukin-1 signaling, developed by Eleven Biotherapeutics as an eye-drop treatment for dry eye disease and allergic conjunctivitis.
ITA-VALI-DEM study
ITA-VALI-DEM (NCT06701630) is an observational study by Casa di Cura IGEA, Milan, validating Italian versions of BADL, IADL, E-Cog, NPI-Q, and M-FAQ scales in 390 adults aged 60 and over across SCD, MCI, mild dementia, and unimpaired groups.
Itacitinib
Itacitinib (INCB039110), an oral JAK1-selective inhibitor from Incyte, was tested in psoriasis, rheumatoid arthritis, myelofibrosis, and GVHD; its pivotal phase 3 acute GVHD trial (GRAVITAS-301) failed its primary endpoint.
Italian plague of 1629–1631
The Italian plague of 1629–1631, also known as the Great Plague of Milan, was a bubonic plague epidemic that killed about a third of northern Italy's population.
ItalianCNA trial
ItalianCNA (NCT05751330) is a GIMSI-sponsored multicenter Italian trial of right atrial cardioneuroablation for asystolic reflex syncope documented by implantable loop recorder; 28 patients showed asystole burden falling from 0.89 to 0.11 episodes per month.
Itch
Itch (pruritus) is an unpleasant skin sensation provoking scratching, defined by Hafenreffer in 1660. Carried by C fibers, relayed via spinal GRPR neurons; histaminergic and nonhistaminergic forms; chronic itch lasts 6+ weeks and resists antihistamines.
Itching of skin
Itching of skin, medically called pruritus, is an unpleasant sensation of the skin and nearby mucous membranes that triggers scratching; chronic itch lasts 6 weeks or more.
Itepekimab
Itepekimab (REGN3500, SAR440340) is a fully human anti-IL-33 IgG4P monoclonal antibody from Sanofi and Regeneron for COPD, asthma, and rhinosinusitis; AERIFY-1 met its endpoint, AERIFY-2 did not.
Iterative reconstruction
Iterative reconstruction is a medical imaging method that repeatedly refines an image estimate against measured data, cutting noise and CT radiation dose; it became routine in CT around 2008.
ITM2B amyloidosis
ITM2B amyloidosis: autosomal dominant cerebral amyloid angiopathy from ITM2B (BRI2) stop-codon mutations, causing familial British dementia (ABri peptide) and familial Danish dementia (ADan peptide), with dementia, ataxia, and vascular amyloid deposits.
Itolizumab
Itolizumab (T1h, EQ001, ALZUMAb) is a humanized anti-CD6 IgG1 monoclonal antibody that blocks CD6-ALCAM T-cell co-stimulation. Approved in India in 2013 for plaque psoriasis and given emergency use authorization in 2020 for COVID-19 cytokine release syndrome.
Itopride
Itopride (Ganaton) is a benzamide gastroprokinetic combining dopamine D2 antagonism and acetylcholinesterase inhibition, metabolized by flavin-containing monooxygenase, used for functional dyspepsia with modest pooled efficacy and no QT prolongation.
Itraconazole
Itraconazole (Sporanox, SUBA-itraconazole) is a Janssen-discovered triazole antifungal inhibiting fungal 14-alpha-demethylase; used for histoplasmosis, blastomycosis, aspergillosis, and onychomycosis, with CYP3A4 interactions and TDM.
Itrifal Ustukhuddus
依提尔非里欧斯提胡都斯 (Itrifal Ustukhuddus, 伊提日非力 欧斯提胡都斯) is a semi-solid Unani electuary based on Lavandula stoechas and three Terminalia chebula forms, used for chronic headache, catarrh, and sinusitis, dose 5-10 g.
Ivabradine
Ivabradine (Corlanor, Procoralan) is a selective HCN/I_f channel blocker that slows the sinus node without affecting blood pressure or contractility. Approved for HFrEF (LVEF ≤35%, HR ≥70 bpm) and pediatric dilated cardiomyopathy; SHIFT showed fewer heart-failure hospitalizations, no mortality benefit.
Ivan Raimi
Ivan Mitchell Raimi (born 1956) is an American emergency medicine physician and screenwriter, older brother of Sam and Ted Raimi, co-writer of Darkman, Army of Darkness, Spider-Man 3, and Drag Me to Hell.
Ivarmacitinib
Ivarmacitinib (艾玛昔替尼, SHR0302, brand Asuda) is an oral selective JAK1 inhibitor by Jiangsu Hengrui, first approved in China in 2025 for rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and alopecia areata.
Ivermectin
Ivermectin, also sold as Stromectol, Mectizan, and Ivomec, is a broad-spectrum avermectin-class antiparasitic drug used against roundworms, mites, and lice; developers Campbell and Ōmura shared the 2015 Nobel Prize.
IVIC syndrome
IVIC syndrome, also called oculo-oto-radial syndrome (OMIM 147750), is a very rare autosomal dominant SALL4-related malformation syndrome with radial ray defects, carpal fusion, strabismus, mixed hearing loss, and mild thrombocytopenia.
Ivonescimab (AK112)
Ivonescimab (依沃西单抗, AK112/SMT112) is Akeso's first-in-class tetravalent Fc-silent bispecific antibody blocking PD-1 and VEGF, licensed to Summit Therapeutics for up to $5 billion; approved in China for NSCLC, with HARMONi-2 beating pembrolizumab on PFS and OS.
Ivor Lewis esophagectomy
Ivor Lewis esophagectomy is a two-stage operation for esophageal cancer that removes the esophagus through the abdomen and right chest, joining the stomach to it inside the chest.
Ivuxolimab
Ivuxolimab (PF-04518600, PF-8600), Pfizer's fully human IgG2 agonistic anti-OX40 (CD134) monoclonal antibody for cancer immunotherapy; phase I trials showed no DLTs, 5.8% partial responses, and combination data with utomilumab.
Ixabepilone
Ixabepilone (Ixempra, BMS-247550, aza-epothilone B) is a semisynthetic epothilone B lactam microtubule inhibitor, first FDA-approved in October 2007 for anthracycline- and taxane-resistant metastatic or locally advanced breast cancer.
Ixazomib
Ixazomib (Ninlaro) is the first oral proteasome inhibitor, approved in 2016 with lenalidomide and dexamethasone for relapsed multiple myeloma after one prior therapy; TOURMALINE-MM1 improved PFS but not overall survival.
IxCell human umbilical cord MSC injection (hUC-MSC-O)
IxCell hUC-MSC-O is an allogeneic human umbilical cord mesenchymal stem cell injection for knee osteoarthritis by Shanghai Ixcell Biopharmaceutical, licensed for clinical trials in China in 2019.
Ixekizumab
Ixekizumab (Taltz), Eli Lilly's humanized IgG4 monoclonal antibody against interleukin-17A, injected subcutaneously for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis; first FDA-approved March 22, 2016.
Ixiaro
Ixiaro (JESPECT) is Valneva's inactivated Vero cell culture-derived Japanese encephalitis vaccine, the only JE vaccine licensed in the United States, approved 2009 for adults and 2013 for children aged 2 months and older, given as two doses.
Izalontamab
Izalontamab (SI-B001) is an experimental bispecific antibody that targets EGFR and HER3 on cancer cells to block tumor growth; it also serves as the targeting part of izalontamab brengitecan, an antibody-drug conjugate.
Izalontamab brengitecan
Izalontamab brengitecan (伦康依隆妥单抗, iza-bren, BL-B01D1, BMS-986507) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate with a topoisomerase I inhibitor payload, approved in China in 2026 for nasopharyngeal and esophageal cancers.